Q4 2025 Taysha Gene Therapies Inc Earnings Call Transcript
Key Points
- Taysha Gene Therapies Inc (TSHA) announced compelling Phase I/II data for TSHA-102, showing a 100% response rate in patients with Rett syndrome.
- The company received FDA breakthrough therapy designation for TSHA-102, facilitating a potentially streamlined path toward regulatory approval.
- TSHA-102 has shown a favorable safety profile with no treatment-related serious adverse events observed.
- Taysha has secured FDA alignment on pivotal trial designs, supporting a broad label for TSHA-102 for patients aged two years and older.
- The company has a strong cash position, with $319.8 million in cash and cash equivalents, sufficient to fund operations into 2028.
- Research and development expenses increased significantly to $86.4 million in 2025, driven by higher compensation and clinical trial costs.
- General and administrative expenses rose to $33.9 million, partly due to higher legal and professional fees.
- Net loss for 2025 was $109 million, an increase from the previous year's loss of $89.3 million.
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- There is a potential delay in BLA submission if the FDA requires 12 months of data instead of the anticipated six months.
Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies full year 2025 financial results conference call. (Operator instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Hayleigh Collins, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Thank you. Good morning, and welcome to Taysha's full-year 2025 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the full year ended December 31, 2025. A copy of this press release is available on the company's website and through our SEC filings.
Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
